Saniona AB (publ) (STO:SANION)

Market Cap	2.14B +147.4%
Revenue (ttm)	434.40M +29.8%
Net Income	284.67M +50.9%
EPS	2.15 +22.2%
Shares Out	138.03M
PE Ratio	7.23
Forward PE	37.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,365,864
Average Volume	654,848
Open	15.30
Previous Close	15.20
Day's Range	13.92 - 16.21
52-Week Range	6.02 - 28.30
Beta	1.28
RSI	41.10
Earnings Date	May 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.